CTLA4 and colitis: In patients with metastatic melanoma that were given ICI therapy that included anti–CTLA-4, an increased number if IL-17A–secreting CD4 T-cells (TH17) was observed in peripheral circulation of those who developed colitis (von Euw et al., 2009; Anderson et al., 2019).